Abstract:Importance: The population prevalence of cardiac transthyretin amyloidosis (ATTR) caused by pathogenic variation in the TTR gene (vATTR) is unknown. Objective: To estimate the population prevalence of disease-causing TTR variants and evaluate associated phenotypes and outcomes. Design, setting, and participants: This population-based cohort study analyzed UK Biobank (UKB) participants with whole-exome sequencing, electrocardiogram, and cardiovascular magnetic resonance data. Participants were enrolled from 2006 to 2010, with a median follow-up of 12 (IQR, 11-13) years (cutoff date for the analysis, March 12, 2024). Sixty-two candidate TTR variants were extracted based on rarity (minor allele frequency ≤0.0001) and/or previously described associations with amyloidosis if more frequent. Exposure: Carrier status for TTR variants. Main outcomes and measures: Associations of TTR carrier status with vATTR prevalence and cardiovascular imaging and electrocardiogram traits were explored using descriptive statistics. Associations between TTR carrier status and atrial fibrillation, conduction disease, heart failure, and all-cause mortality were evaluated using adjusted Cox proportional hazards models. Genotypic and diagnostic concordance was examined using International Statistical Classification of Diseases, Tenth Revision codes from the hospital record. Results: The overall cohort included 469 789 UKB participants (mean [SD] age, 56.5 [8.1] years; 54.2% female and 45.8% male). A likely pathogenic/pathogenic (LP/P) TTR variant was detected in 473 (0.1%) participants, with Val142Ile being the most prevalent (367 [77.6%]); 91 individuals (0.02%) were carriers of a variant of unknown significance . The overall prevalence of LP/P variants was 0.02% (105 of 444 243) in participants with European ancestry and 4.3% (321 of 7533) in participants with African ancestry. The LP/P variants were associated with higher left ventricular mass indexed to body surface area (β = 4.66; 95% CI, 1.87-7.44), and Val142Ile was associated with a longer PR interval (β = 18.34; 95% CI, 5.41-31.27). The LP/P carrier status was associated with a higher risk of heart failure (hazard ratio [HR], 2.68; 95% CI, 1.75-4.12) and conduction disease (HR, 1.88; 95% CI, 1.25-2.83). Higher all-cause mortality risk was observed for non-Val142Ile LP/P variants (HR, 1.98; 95% CI, 1.06-3.67). Thirteen participants (2.8%) with LP/P variants had diagnostic codes compatible with cardiac or neurologic amyloidosis. Variants of unknown significance were not associated with outcomes. Conclusions and relevance: This study found that approximately 1 in 1000 UKB participants were LP/P TTR variant carriers, exceeding previously reported prevalence. The findings emphasize the need for clinical vigilance in identifying individuals at risk of developing vATTR and associated poor outcomes.

High-proportion spliced-in titin truncating variants in African and European ancestry in the All of Us Research Program

Titin truncating variants, cardiovascular risk factors and the risk of atrial fibrillation and heart failure

Titin-Truncating variants Predispose to Dilated Cardiomyopathy in Diverse Populations

Study on the Correlation Between CETP TaqIB,KCNE1 S38G and Enos T-786C Gene Polymorphisms for Predisposition and Non-Valvular Atrial Fibrillation

Exon 47 Skipping of Fibrillin-1 Leads Preferentially to Cardiovascular Defects in Patients with Thoracic Aortic Aneurysms and Dissections

Carpal Tunnel Syndrome and Transthyretin Amyloidosis in the All of Us Research Program

Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults

A Titin Missense Variant Causes Atrial Fibrillation

Identification of Rare Variants in Tnni3 with Atrial Fibrillation in A Chinese Geneid Population

Abstract 13259: Large-Scale Plasma Proteomics Identifies C1QTNF1 as a Potential Causal Risk Factor for Aortic Stenosis

Clinical Characteristics and Outcomes in Patients With Atrial Fibrillation and Pathogenic TTN Variants

Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US

Proteomic Profile of the ICAM1 p.K56M HFpEF Risk Variant

Clinical Significance of Variants in the TTN Gene in a Large Cohort of Patients with Sporadic Dilated Cardiomyopathy

Association of Protein Function-Altering Variants with Cardiometabolic Traits: the Strong Heart Study

Pathogenic cardiomyopathy gene variants inform prognosis in atrial fibrillation: results from exome sequencing in over 17,000 patients in TIMI trials

Cardiovascular Burden of the V142I Transthyretin Variant

Association between polymorphisms in the signal transducer and activator of transcription and dilated cardiomyopathy in the Chinese Han population

High-Sensitivity Cardiac Troponins I and T and Cardiovascular Outcomes: Findings from the Systolic Blood Pressure Intervention Trial (SPRINT)

Novel missense variant in TTN cosegregating with familial atrioventricular block.

Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population